Adjuvant IFNα2 therapy of melanoma
- 27 June 1998
- journal article
- editorial
- Published by Elsevier in The Lancet
- Vol. 351 (9120) , 1901-1903
- https://doi.org/10.1016/s0140-6736(05)78608-6
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group.Journal of Clinical Oncology, 1998
- Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684.Journal of Clinical Oncology, 1997
- Recent Advances in the Care of the Patient with Malignant MelanomaAnnals of Surgery, 1997
- Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study.Journal of Clinical Oncology, 1996
- Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.Journal of Clinical Oncology, 1996
- Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma VaccineAnnals of Surgery, 1992
- Interferon Alfa-2a Therapy for Life-Threatening Hemangiomas of InfancyNew England Journal of Medicine, 1992
- Thickness, Cross-Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous MelanomaAnnals of Surgery, 1970